Back to list
Google DeepMind Launches AlphaGenome 2 to Unravel Cellular Roots of Disease
Industry NewsAlphaGenome 2Google DeepMindGenetics

Google DeepMind Launches AlphaGenome 2 to Unravel Cellular Roots of Disease

Researchers at Google DeepMind have unveiled AlphaGenome 2, a next-generation AI model designed to predict how genetic variants affect specific human cell types and states. Serving as the successor to the original AlphaGenome, the new model bridges single-cell biology and human genetics. Trained on over 100 million individual cell profiles across 68 tissues, AlphaGenome 2 provides scientists with a detailed view of how changes in DNA impact cell-specific gene expression. This capability helps uncover cellular drivers of disease that are often missed by broad-tissue models, pointing the way toward new treatments and offering enhanced variant predictive performance for non-commercial research via the AlphaGenome API.

The Verge

Key Takeaways

  • Google DeepMind has introduced AlphaGenome 2, a next-generation DNA sequence model bridging single-cell biology and human genetics.
  • The model is trained on more than 100 million individual cell profiles across 68 tissues to predict how genetic variants impact specific human cell types and states.
  • AlphaGenome 2 identifies nearly twice as many variants that change gene expression in cells compared to the previous state-of-the-art model.
  • The tool is designed to help researchers uncover cellular root causes of disease and is made available for non-commercial research through the AlphaGenome API.

In-Depth Analysis

Bridging Single-Cell Biology and Human Genetics

Researchers at Google DeepMind developed AlphaGenome 2 to tackle a notoriously difficult problem in genetics: understanding how subtle DNA variations affect gene expression across different cells. Every cell in the human body carries the same DNA blueprint, yet distinct cell types and states—such as a heart muscle cell or an immune cell—switch different genes on or off to perform their specific functions. While global initiatives like the Human Cell Atlas map gene expression for millions of cells, predicting how subtle DNA variations alter this expression has remained an unsolved challenge. AlphaGenome 2 addresses this by zooming in from broad tissue averages to individual cell types and cell states.

Architectural Improvements and Enhanced Predictive Performance

By redesigning the model's architecture and training it on extensive data including over 100 million individual cell profiles across 68 tissues, AlphaGenome 2 achieves a step-change improvement in variant predictive performance. Unlike broad-tissue models, this conditional model structure allows researchers to predict variant effects in disease-relevant cells that would otherwise be missed. Furthermore, it enables predictions for cell and disease states that the model has not encountered during training, identifying nearly twice as many variants that alter gene expression in cells compared to DeepMind's previous model.

Industry Impact

The introduction of AlphaGenome 2 represents a major milestone for computational genomics and disease research. By turning static cell atlases into predictive engines, the tool helps scientists prioritize and interpret variant effects in rare diseases, complex traits, and fundamental biology. Providing access to non-commercial researchers through the AlphaGenome API accelerates the path toward uncovering the cellular drivers of disease and developing targeted medical treatments.

Frequently Asked Questions

Question

What is AlphaGenome 2?

Answer

AlphaGenome 2 is a next-generation DNA sequence AI model developed by Google DeepMind that predicts how DNA sequences and their variations impact specific human cell types and cell states.

Question

How was AlphaGenome 2 trained?

Answer

The model was trained on more than 100 million individual cell profiles across 68 tissues, allowing it to bridge single-cell biology and human genetics.

Question

How can researchers access AlphaGenome 2?

Answer

Google DeepMind makes AlphaGenome 2 available for non-commercial research through the AlphaGenome API.

Related News

Japanese Investors Seek $9.4 Billion in Anthropic IPO Shares and Receive $2.98 Billion
Industry News

Japanese Investors Seek $9.4 Billion in Anthropic IPO Shares and Receive $2.98 Billion

Japanese investors sought $9.4 billion in shares in Anthropic’s initial public offering and were ultimately allotted US$2.98 billion, Tech in Asia reported. The report cites a filing for the final allotment. The two figures describe different things: the $9.4 billion is the reported value of the shares Japanese investors sought, while the US$2.98 billion is the value of the shares they were allotted. The allotment was therefore lower than the amount sought. The available report does not identify the investors, explain why the allotment was lower, or give the overall size of the offering. It documents demand and allocation for Japanese investors without establishing how that demand compared with interest from other investors.

Apple Is Hiring to Build an AI Agent That Can Work Across Apps
Industry News

Apple Is Hiring to Build an AI Agent That Can Work Across Apps

Apple is looking for an engineer to lead the creation of its own agentic AI assistant, according to a job listing spotted by Bloomberg and reported by The Verge. The assistant is described as being able to browse the web, work across apps, write code, and call services on a user's behalf. The listing is notable for the range of tasks it names: it describes an assistant that does work for users, rather than establishing how any one capability would function. The available report concerns hiring and the scope of the project. It does not announce a release or say which apps and services the assistant would be able to use.

Meta’s Muse Charm AI Wearable May Cost $300, but Meta Has Not Confirmed the Price
Industry News

Meta’s Muse Charm AI Wearable May Cost $300, but Meta Has Not Confirmed the Price

Meta’s upcoming Muse Charm AI wearable may cost $300, according to a TechCrunch AI article by Lucas Ropek that cites reporting from The Information. Meta did not deny the reporting, saying only that it would “have more to share soon” about the wearable. The distinction is that $300 is a reported possibility, not an official price. Meta’s response indicates that it expects to share more information, but it does not say when that will happen or whether the next update will address pricing. For now, the article establishes that Muse Charm is an upcoming AI wearable and that $300 has been reported as a possible price.